QSAR models and scaffold-based analysis of non-nucleoside HIV RT inhibitors

Chemometrics and Intelligent Laboratory Systems

Volumn 148, Issue , 2015, Pages 134-144

  Nizami, Bilal ^a   Tetko, Igor V ^b,c   Koorbanally, Neil A ^a   Honarparvar, Bahareh ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c KAZAN FEDERAL UNIVERSITY   (Russian Federation)

Author keywords

HIV reverse transcriptase (HIV RT); Matched molecular pair analysis (MMPA); Molecular docking; Non nucleoside reverse transcriptase (NNRT) pyrimidine derivatives; Quantitative structure activity relationship (QSAR)

Indexed keywords

MOLECULAR SCAFFOLD; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE;

ANALYTICAL PARAMETERS; ANTIVIRAL ACTIVITY; ARTICLE; ARTIFICIAL NEURAL NETWORK; CONTROLLED STUDY; DRUG DESIGN; DRUG STRUCTURE; MATCHED MOLECULAR PAIR ANALYSIS; MOLECULAR DOCKING; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SIMULATION; VALIDATION STUDY;

EID: 84944212427     PISSN: 01697439     EISSN: 18733239     Source Type: Journal    
DOI: 10.1016/j.chemolab.2015.09.011     Document Type: Article

References (67)

1. WHO's Global Health Observatory (Access date 20/06/2015). http://www.who.int/gho/hiv/en/.
2. Tronchet J.M., Seman M. Nonnucleoside inhibitors of HIV-1 reverse transcriptase: from the biology of reverse transcription to molecular design. Curr. Top. Med. Chem. 2003, 3:1496-1511.
3. Reynolds C., de Koning C.B., Pelly S.C., van Otterlo W.A., Bode M.L. In search of a treatment for HIV--current therapies and the role of non-nucleoside reverse transcriptase inhibitors (NNRTIs). Chem. Soc. Rev. 2012, 41:4657-4670.
4. Patel H.M., Noolvi M.N., Sharma P., Jaiswal V., Bansal S., Lohan S., et al. Quantitative structure-activity relationship (QSAR) studies as strategic approach in drug discovery. Med. Chem. Res. 2014, 23(12):4991-5007.
5. Nantasenamat C., Isarankura-Na-Ayudhya C., Naenna T., Prachayasittikul V. A practical overview of quantitative structure-activity relationship. EXCLI J. 2009, 8:74-88.
6. Sushko Y., Novotarskyi S., Korner R., Vogt J., Abdelaziz A., Tetko I.V. Prediction-driven matched molecular pairs to interpret QSARs and aid the molecular optimization process. J. Cheminform. 2014, 6:48.
7. Cumming J.G., Davis A.M., Muresan S., Haeberlein M., Chen H. Chemical predictive modelling to improve compound quality. Nat. Rev. Drug Discov. 2013, 12:948-962.
8. Makatini M.M., Petzold K., Sriharsha S.N., Soliman M.E., Honarparvar B., Arvidsson P.I., et al. Pentacycloundecane-based inhibitors of wild-type C-South African HIV-protease. Bioorg. Med. Chem. Lett. 2011, 21:2274-2277.
9. Makatini M.M., Petzold K., Arvidsson P.I., Honarparvar B., Govender T., Maguire G.E.M., et al. Synthesis, screening and computational investigation of pentacycloundecane-peptoids as potent CSA-HIV PR inhibitors. Eur. J. Med. Chem. 2012, 57:459-467.
10. Toropova A.P., Toropov A.A., Veselinovic J.B., Miljkovic F.N., Veselinovic A.M. QSAR models for HEPT derivates as NNRTI inhibitors based on Monte Carlo method. Eur. J. Med. Chem. 2014, 77:298-305.
11. Douali L., Villemin D., Zyad A., Cherqaoui D. Artificial neural networks: non-linear QSAR studies of HEPT derivatives as HIV-1 reverse transcriptase inhibitors. Mol. Divers. 2004, 8:1-8.
12. Afantitis A., Melagraki G., Sarimveis H., Koutentis P.A., Markopoulos J., Igglessi-Markopoulou O. A novel simple QSAR model for the prediction of anti-HIV activity using multiple linear regression analysis. Mol. Divers. 2006, 10:405-414.
13. Bazoui H., Zahouily M., Boulajaaj S., Sebti S., Zakarya D. QSAR for anti-HIV activity of HEPT derivatives. SAR QSAR Environ. Res. 2002, 13:567-577.
14. NIAID Division of AIDS Anti-HIV/OI/TB Therapeutics Database (Available from: chemdb.niaid.nih.gov, Access date June 2014).
15. Chen H., Bai J., Jiao L., Guo Z., Yin Q., Li X. Design, microwave-assisted synthesis and HIV-RT inhibitory activity of 2-(2,6-dihalophenyl)-3-(4,6-dimethyl-5-(un)substituted-pyrimidin-2-yl)thiazolidin -4-ones. Bioorg. Med. Chem. 2009, 17:3980-3986.
16. Costi R., Di Santo R., Artico M., Massa S., Lavecchia A., Marceddu T., et al. Structure-activity relationship studies on potential non-nucleoside DABO-like inhibitors of HIV-1 reverse transcriptase. Antivir. Chem. Chemother. 2000, 11:117-133.
17. Kertesz D.J., Brotherton-Pleiss C., Yang M., Wang Z., Lin X., Qiu Z., et al. Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses. Bioorg. Med. Chem. Lett. 2010, 20:4215-4218.
18. Mai A., Artico M., Ragno R., Sbardella G., Massa S., Musiu C., et al. 5-Alkyl-2-alkylamino-6-(2,6-difluorophenylalkyl)-3,4-dihydropyrimidin-4(3H)-ones, a new series of potent, broad-spectrum non-nucleoside reverse transcriptase inhibitors belonging to the DABO family. Bioorg. Med. Chem. 2005, 13:2065-2077.
19. Mai A., Artico M., Sbardella G., Massa S., Loi A.G., Tramontano E., et al. Synthesis and anti-HIV-1 activity of thio analogues of dihydroalkoxybenzyloxopyrimidines. J. Med. Chem. 1995, 38:3258-3263.
20. Mai A., Artico M., Sbardella G., Massa S., Novellino E., Greco G., et al. 5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3,4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives. J. Med. Chem. 1999, 42:619-627.
21. Mai A., Artico M., Sbardella G., Quartarone S., Massa S., Loi A.G., et al. Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series. J. Med. Chem. 1997, 40:1447-1454.
22. Mai A., Sbardella G., Artico M., Ragno R., Massa S., Novellino E., et al. Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-on es as non-nucleoside inhibitors of HIV-1 reverse transcriptase. J. Med. Chem. 2001, 44:2544-2554.
23. Nugent R.A., Schlachter S.T., Murphy M.J., Cleek G.J., Poel T.J., Wishka D.G., et al. Pyrimidine thioethers: a novel class of HIV-1 reverse transcriptase inhibitors with activity against BHAP-resistant HIV. J. Med. Chem. 1998, 41:3793-3803.
24. Cao D.S., Liang Y.Z., Xu Q.S., Li H.D., Chen X. A new strategy of outlier detection for QSAR/QSPR. J. Comput. Chem. 2010, 31:592-602.
25. Qin H., Liu C., Zhang J., Guo Y., Zhang S., Zhang Z., et al. Synthesis and biological evaluation of novel 2-arylalkylthio-4-amino-6-benzyl pyrimidines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett. 2010, 20:3003-3005.
26. Ragno R., Mai A., Sbardella G., Artico M., Massa S., Musiu C., et al. Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-o nes as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant. J. Med. Chem. 2004, 47:928-934.
27. Rao A., Balzarini J., Carbone A., Chimirri A., De Clercq E., Monforte A.M., et al. 2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors. Antivir. Res. 2004, 63:79-84.
28. Tang G., Kertesz D.J., Yang M., Lin X., Wang Z., Li W., et al. Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses. Bioorg. Med. Chem. Lett. 2010, 20:6020-6023.
29. Zhang L., Tang X., Cao Y., Wu S., Zhang Y., Zhao J., et al. Synthesis and biological evaluation of novel 2-arylalkylthio-5-iodine-6-substituted-benzyl-pyrimidine-4(3H)-ones as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Molecules 2014, 19:7104-7121.
30. Ludovici D.W., De Corte B.L., Kukla M.J., Ye H., Ho C.Y., Lichtenstein M.A., et al. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. Bioorg. Med. Chem. Lett. 2001, 11:2235-2239.
31. Sushko I., Novotarskyi S., Korner R., Pandey A.K., Rupp M., Teetz W., et al. Online chemical modeling environment (OCHEM): web platform for data storage, model development and publishing of chemical information. J. Comput. Aided Mol. Des. 2011, 25:533-554.
32. Tramontano E., Cheng Y.C. HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587. Biochem. Pharmacol. 1992, 43:1371-1376.
33. Balzarini J., Perez-Perez M.J., San-Felix A., Camarasa M.J., Bathurst I.C., Barr P.J., et al. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5'- (4'-amino-1',2'-oxathiole-2',2'-dioxide)thymine (TSAO-T). J. Biol. Chem. 1992, 267:11831-11838.
34. Kalliokoski T., Kramer C., Vulpetti A., Gedeck P. Comparability of mixed IC(5)(0) data-a statistical analysis. PLoS One 2013, 8.
35. Meng G., Liu Y., Zheng A., Chen F., Chen W., De Clercq E., et al. Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors. Eur. J. Med. Chem. 2014, 82:600-611.
36. Liu Z., Chen W., Zhan P., De Clercq E., Pannecouque C., Liu X. Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization. Eur. J. Med. Chem. 2014, 87:52-62.
37. Yang S., Pannecouque C., Daelemans D., Ma X.D., Liu Y., Chen F.E., et al. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors. Eur. J. Med. Chem. 2013, 65:134-143.
38. Tetko I.V. Associative neural network. Methods Mol. Biol. 2008, 458:185-202.
39. Tetko I.V. Neural network studies. 4. Introduction to associative neural networks. J. Chem. Inf. Comput. Sci. 2002, 42:717-728.
40. Tollenaere T. Supersab-fast adaptive back propagation with good scaling properties. Neural Netw. 1990, 3:3:561-3:573.
41. Matthias Dehmer K.V., Bonchev Danail Statistical Modelling of Molecular Descriptors in QSAR/QSPR 2012, Wiley-Blackwell. F. Emmert-Streib (Ed.).
42. Jens Sadowski J.G., Klebe Gerhard Comparison of automatic three-dimensional model builders using 639 x-ray structures. J. Chem. Inf. Model. 1994, 34:701-1028.
43. Whitley D.C., Ford M.G., Livingstone D.J. Unsupervised forward selection: a method for eliminating redundant variables. J. Chem. Inf. Comput. Sci. 2000, 40:1160-1168.
44. Breiman L. Bagging predictors. Mach. Learn. 1996, 24:123-140.
45. Tetko I.V., Novotarskyi S., Sushko I., Ivanov V., Petrenko A.E., Dieden R., et al. Development of dimethyl sulfoxide solubility models using 163,000 molecules: using a domain applicability metric to select more reliable predictions. J. Chem. Inf. Model. 2013, 53:1990-2000.
46. Hopkins A.L., Ren J., Esnouf R.M., Willcox B.E., Jones E.Y., Ross C., et al. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J. Med. Chem. 1996, 39:1589-1600.
47. Bernstein F.C., Koetzle T.F., Williams G.J., Meyer E.F., Brice M.D., Rodgers J.R., et al. The Protein Data Bank: a computer-based archival file for macromolecular structures. Arch. Biochem. Biophys. 1978, 185:584-591.
48. Frisch M.J., Trucks G.W., Schlegel H.B., Scuseria G.E., Robb M.A., Cheeseman J.R., et al. Gaussian 09 2009, Gaussian, Inc., Wallingford, CT, USA.
49. Stewart J.J. Optimization of parameters for semiempirical methods V: modification of NDDO approximations and application to 70 elements. J. Mol. Model. 2007, 13:1173-1213.
50. Forli S. Raccoon|AutoDock VS: an automated tool for preparing AutoDock virtual screenings, (accessed 01/12/2014). http://autodock.scripps.edu/resources/raccoon.
51. Sanner M.F. Python: a programming language for software integration and development. J. Mol. Graph. Model. 1999, 17:57-61.
52. Trott O., Olson A.J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010, 31:455-461.
53. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19:1639-1662.
54. Hussain J., Rea C. Computationally efficient algorithm to identify matched molecular pairs (MMPs) in large data sets. J. Chem. Inf. Model. 2010, 50:339-348.
55. Holm S. A simple sequentially rejective multiple test procedure. Scand. J. Stat. 1979, 6:65-70.
56. Vorberg S., Tetko I.V. Modeling the biodegradability of chemical compounds using the Online CHEmical Modeling Environment (OCHEM). Mol. Inf. 2014, 33(1):73-85.
57. Zhu H., Tropsha A., Fourches D., Varnek A., Papa E., Gramatica P., et al. Combinatorial QSAR modeling of chemical toxicants tested against Tetrahymena pyriformis. J. Chem. Inf. Model. 2008, 48:766-784.
58. Tetko I.V., Bruneau P., Mewes H.W., Rohrer D.C., Poda G.I. Can we estimate the accuracy of ADME-Tox predictions?. Drug Discov. Today 2006, 11:700-707.
59. Tetko I.V., Sushko I., Pandey A.K., Zhu H., Tropsha A., Papa E., et al. Critical assessment of QSAR models of environmental toxicity against Tetrahymena pyriformis: focusing on applicability domain and overfitting by variable selection. J. Chem. Inf. Model. 2008, 48:1733-1746.
60. Sushko I., Novotarskyi S., Korner R., Pandey A.K., Cherkasov A., Li J., et al. Applicability domains for classification problems: benchmarking of distance to models for Ames mutagenicity set. J. Chem. Inf. Model. 2010, 50:2094-2111.
61. Consonni V., Todeschini R. Handbook of Molecular Descriptors 2000, Wiley-VCH, Weinheim; New York.
62. Das K., Lewi P.J., Hughes S.H., Arnold E. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog. Biophys. Mol. Biol. 2005, 88:209-231.
63. Carta A., Pricl S., Piras S., Fermeglia M., La Colla P., Loddo R. Activity and molecular modeling of a new small molecule active against NNRTI-resistant HIV-1 mutants. Eur. J. Med. Chem. 2009, 44:5117-5122.
64. Verma R.P., Hansch C. An approach toward the problem of outliers in QSAR. Bioorg. Med. Chem. 2005, 13:4597-4621.
65. Kim K.H. Outliers in SAR and QSAR: 2. Is a flexible binding site a possible source of outliers?. J. Comput. Aided Mol. Des. 2007, 21:421-435.
66. Kim K.H. Outliers in SAR and QSAR: is unusual binding mode a possible source of outliers?. J. Comput. Aided Mol. Des. 2007, 21:63-86.
67. Tetko I.V. The perspectives of computational chemistry modeling. J. Comput. Aided Mol. Des. 2012, 26:135-136.